10/09/2019 12:00 AM EDT
Source: World Health Organization, Pan American Health Organization (PAHO). Published: 10/9/2019. This 60-page manual provides technical guidelines for the strategic use of indoor residual spraying for Aedes aegypti mosquito control (IRS-Aedes) in urban areas, and compiles and standardizes the criteria, instruments, technical parameters, and equipment, as well as the application technique, for strategic integration of IRS-Aedes in Aedes aegypti control programs. Given the absence of a specific treatment and vaccines against dengue, chikungunya, and Zika, and the limitations of current vector control strategies, the World Health Organization has urged greater use of the available alternatives for improving control of the Aedes aegypti mosquito vector, together with complementary activities. (PDF)
10/01/2019 12:00 AM EDT
Source: World Health Organization (WHO). Published: 10/2019. This six-page document describes the emergency use assessment and listing for Ebola virus disease in vitro diagnostics for the OraQuick® Ebola Rapid Antigen Test Kit. It consists of a desktop review of selected manufacturing and quality management system documentation; the review of any existing documentary evidence of safety and performance; and a limited performance evaluation of relevant performance characteristics of the product. (PDF)
10/01/2019 12:00 AM EDT
Source: Substance Abuse and Mental Health Services Administration (SAMHSA). Published: 10/2019. This 48-page provides public officials, as well as others involved in disaster and emergency communications, with information about effective communication, working with the media, using social media, addressing errors, and controlling rumors. It focuses on techniques for responding to and cooperating with the media in conveying information; ways to deliver messages before, during, and after a public health crisis; and tools of the trade of media relations and public communications. (PDF)
08/22/2019 12:00 AM EDT
Source: World Health Organization (WHO). Published: 8/22/2019. This web page provides background information about Zika virus vaccine product development; links to vaccine product development documents that include a fact sheet, technical roadmap for Zika vaccine development, and Target Product Profile for a Zika vaccine for outbreak use; and links to information about consultations and workshops on Zika vaccine product development. (Text)
08/01/2019 12:00 AM EDT
Source: World Health Organization (WHO). Published: 8/2019. In 2018 -2019, the World Health Organization, in collaboration with a working group of independent subject matter experts, developed Preferred Product Characteristics (PPC) for a Zika virus vaccine for endemic use. This nine-page document provides a table that details a vaccine characteristic, what is preferred, and product development considerations and assumptions. (PDF)
07/01/2019 12:00 AM EDT
The aim of this 31-page briefing paper is to review existing research on the traumatic impact of hate-based violence and the mental health needs of survivors and communities affected by this type of violence. Understanding how hate-based violence can lead to serious and potentially chronic traumatic stress reactions, including but not limited to post-traumatic stress disorder (PTSD) and complex forms of traumatic stress symptoms, can provide a framework for reducing the stigma experienced by survivors and increasing their access to effective treatments. (PDF)
06/01/2019 12:00 AM EDT
Source: World Health Organization (WHO). Published: 6/2019. This four-page document describes the 2019 updated emergency use assessment and listing for Ebola virus disease in vitro diagnostics for FilmArray Biothreat-E. The FilmArray Biothreat-E test is a qualitative multiplexed nucleic acid-based in vitro diagnostic (IVD) test intended for the presumptive detection of Ebola Zaire virus (detected in the West Africa outbreak in 2014) in whole blood specimens or undiluted urine specimens. (PDF)
05/01/2019 12:00 AM EDT
Source: World Health Organization (WHO). Published: 5/2019. This 10-page roadmap aims to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epidemic of 2014-2016. The World Health Organization will expedite pre-qualification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the U.S. Food and Drug Administration. (PDF)
01/01/2019 12:00 AM EST
Source: World Health Organization (WHO). Published: 1/2019. This 43-page document describes the 2019 updated emergency use assessment and listing for Ebola virus disease in vitro diagnostics for Liferiver™ - Ebola Virus (EBOV) Real Time RT-PCR Kit. This kit is an in vitro diagnostic test for the detection of all high pathogenic members of Ebolavirus: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SUDV), Taï Forest ebolavirus (TAFV), and Bundibugyo ebolavirus (BDBV) in blood, serum, or plasma. (PDF)
01/01/2019 12:00 AM EST
Source: World Health Organization (WHO). Published: 1/2019. This 41-page document describes the 2019 updated emergency quality assessment mechanism for Ebola virus disease in vitro diagnostics for RealStar® Filovirus Screen RT-PCR Kit 1.0. This product is a manual in vitro diagnostic test, based on real-time PCR technology, for the qualitative detection and differentiation of Ebola- and Marburg virus- specific RNA in human EDTA plasma. (PDF)
.png)
No hay comentarios:
Publicar un comentario